Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2019 07:30 ET | Source: Orchard Therapeutics

Orchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature Medicine

BOSTON and LONDON, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
January 07, 2019 08:00 ET | Source: Orchard Therapeutics

Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy

Preparing Three Lead Programs for MLD, ADA-SCID and WAS for Regulatory Filings Over the Next Three Years Recently Announced Clinical Proof-of-Concept in X-CGD Demonstrates Platform’s Transformative...
January 02, 2019 16:01 ET | Source: Orchard Therapeutics

Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019

BOSTON and LONDON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
December 14, 2018 07:30 ET | Source: Orchard Therapeutics

Orchard Therapeutics and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing Efficiency

BOSTON and LONDON and MARTINSRIED, Germany, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the...
December 13, 2018 07:30 ET | Source: Orchard Therapeutics

Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California

New facility expected to create more than 100 new jobs, supporting extensive gene therapy pipeline Enhances Orchard’s capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic...
December 05, 2018 07:30 ET | Source: Orchard Therapeutics

Donald B. Kohn, MD, Orchard Therapeutics Scientific Advisory Board Member, Presents Clinical Proof-of-Concept Data for OTL-102 Gene Therapy for the Treatment of Patients with X-CGD at the Presidential Symposium at the 2018 ASH Annual Meeting

BOSTON and LONDON, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of...
November 08, 2018 07:30 ET | Source: Orchard Therapeutics

Orchard Therapeutics Strengthens Global Commercial Leadership Team with Appointments of Heads of US and EMEA Region Commercial Operations

Commercial team preparing for potential gene therapy launches BOSTON and LONDON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a leading commercial-stage biotech company dedicated to...
November 05, 2018 07:00 ET | Source: Orchard Therapeutics

Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option

BOSTON and LONDON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and...
October 30, 2018 22:21 ET | Source: Orchard Therapeutics

Orchard Therapeutics Announces Pricing of Initial Public Offering

BOSTON and LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and...
October 04, 2018 08:00 ET | Source: Orchard Therapeutics

Orchard Therapeutics Receives EMA PRIME Designation for OTL-300, an Investigational Lentiviral Gene Therapy for the Treatment of Transfusion-Dependent Beta-Thalassemia

BOSTON and LONDON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a leading commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through...

Next Page keyboard_arrow_right